Beyond Weight Loss: Association between GLP-1 Medication Use and Patient-Reported Improvements in Confidence, Social Engagement and Food Noise among Adults with Obesity and T2D

Introduction and Objective: While GLP-1s are increasingly used for obesity and T2D, their impact beyond weight and glycemic control is poorly understood. We assessed patient-reported outcomes including confidence, social engagement and food-related cognitive burden. Methods: Data are from the Ipsos Obesity Consumer Monitor: an online survey conducted in Oct-Nov 2025 among general population US adults (18yrs+), including 1,370 GLP-1 users with or without comorbid T2D. We assessed the impact of treatment on patient-reported outcomes on various quality of life (QoL) indicators using statements rated on a 7-point Likert scale. Results: Among 1,370 patients taking GLP-1s for obesity, those with obesity and T2D without additional comorbidities (n=53) reported greater improvements across multiple QoL dimensions compared to patients with obesity alone (n=110), T2D alone (n=40) or those with additional comorbidities (n=254). Notably, patients with both conditions reported significantly higher energy levels (mean 4.85 vs 4.20-4.38 across all other groups, p<0.05). This group also demonstrated greater improvements in healthy eating behaviors (4.78 vs 4.26-4.53), food preparation frequency (4.57 vs 4.01-4.20), exercise (4.64 vs 3.90-4.29), self-confidence (4.57 vs 4.01-4.50) and perceived positive impact on comorbid conditions (4.71 vs 4.00-4.56). Conclusion: Patients with co-occurring obesity and T2D report more favorable outcomes while taking GLP-1s compared to those with either condition alone or with multiple comorbidities. The improvements in energy, healthy behaviors and self-confidence may have implications for clinical practice: patients with both conditions may be particularly well-suited for GLP-1 therapy and clinicians can set expectations for meaningful QoL improvements beyond weight and glycemic endpoints. Further research is warranted to understand the mechanisms underlying enhanced psychosocial benefits in this population. Disclosure: A. Levent: None. M.S. Tan: None. R. Schmuecking: None.